Selenoprotein P Deficiency Is Associated with Early Signs of Kidney Disease and Hospitalization Risk in Heart Failure

Selenium (Se), an essential trace element, is linked to poor prognosis in heart failure (HF) and kidney disease. Se deficiency (serum Se < 70 μg/L) has been associated with increased cardiovascular mortality. Selenoprotein P (SELENOP), the main Se transporter, reflects bioavailable Se. Selective glomerular hypofiltration syndrome (SGHS), defined by a cystatin C-based eGFR < 0.7 of creatinine-based eGFR, signals early kidney dysfunction and worsens HF outcomes. The prognostic role of SELENOP for SGHS and kidney-related hospitalization in HF remains unclear. Purpose: To assess whether SELENOP is associated with SGHS at baseline and future kidney disease hospitalization in acute HF patients. Methods: In 570 patients hospitalized for acute HF, creatinine and cystatin C were analyzed; SELENOP was measured in the first 320 using an immunoassay. Kidney hospitalizations (ICD-10 N17–N19) were identified from regional registries. Logistic and Cox regression models evaluated SELENOP’s association with SGHS and hospitalization risk, adjusting for age, sex, blood pressure, BMI, eGFR and NT-proBNP. Results: Among 320 patients (mean age 75 years, 69% male), 58% had Se deficiency, and 30% had SGHS. During a median 43-month follow-up, 28 patients were hospitalized for kidney disease. Higher SELENOP was linked to lower odds of SGHS (OR 0.69; p = 0.002) and reduced risk of hospitalization for AKI or CKD (HR 0.60; p = 0.010), particularly AKI (HR 0.42; p = 0.002). SELENOP-deficiency (